Tower Research Capital (TRC)’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,433
| Closed | -$247K | – | 7054 |
|
|
2021
Q3 | $247K | Sell |
1,433
-4,677
| -77% | -$612K | 0.01% | 1611 |
|
|
2021
Q2 | $766K | Buy |
6,110
+5,588
| +1,070% | +$705K | 0.02% | 848 |
|
|
2021
Q1 | $71K | Sell |
522
-7,176
| -93% | -$927K | ﹤0.01% | 2849 |
|
|
2020
Q4 | $985K | Buy |
7,698
+6,441
| +512% | +$755K | 0.03% | 531 |
|
|
2020
Q3 | $141K | Sell |
1,257
-13,490
| -91% | -$1.34M | ﹤0.01% | 2872 |
|
|
2020
Q2 | $1.41M | Buy |
+14,747
| New | +$1.42M | 0.06% | 349 |
|
|
2020
Q1 | – | Sell |
-1,237
| Closed | -$66K | – | 4290 |
|
|
2019
Q4 | $66K | Buy |
1,237
+1,048
| +554% | +$47.8K | 0.01% | 1168 |
|
|
2019
Q3 | $7K | Sell |
189
-1,971
| -91% | -$85.5K | ﹤0.01% | 3178 |
|
|
2019
Q2 | $89K | Buy |
+2,160
| New | +$89.4K | 0.01% | 1240 |
|
|
2018
Q4 | – | Sell |
-27
| Closed | -$2K | – | 4576 |
|
|
2018
Q3 | $2K | Buy |
+27
| New | +$1.33K | ﹤0.01% | 3516 |
|
|
2018
Q2 | – | Sell |
-1,500
| Closed | -$59K | – | 4268 |
|
|
2018
Q1 | $59K | Buy |
1,500
+933
| +165% | +$39.7K | 0.01% | 1591 |
|
|
2017
Q4 | $24K | Buy |
567
+65
| +13% | +$2.44K | ﹤0.01% | 1938 |
|
|
2017
Q3 | $19K | Buy |
502
+402
| +402% | +$14K | ﹤0.01% | 2767 |
|
|
2017
Q2 | $3K | Buy |
+100
| New | +$2.9K | ﹤0.01% | 2265 |
|
|
2017
Q1 | – | Sell |
-993
| Closed | -$25K | – | 4209 |
|
|
2016
Q4 | $25K | Buy |
993
+129
| +15% | +$4.09K | ﹤0.01% | 1951 |
|
|
2016
Q3 | $31K | Buy |
+864
| New | +$28.6K | ﹤0.01% | 1391 |
|
|
2016
Q2 | – | Sell |
-20
| Closed | -$1K | – | 5207 |
|
|
2016
Q1 | $1K | Buy |
+20
| New | +$582 | ﹤0.01% | 3868 |
|
|
2015
Q4 | – | Sell |
-873
| Closed | -$22K | – | 5279 |
|
|
2015
Q3 | $22K | Buy |
+873
| New | +$26.2K | ﹤0.01% | 1662 |
|
|
2015
Q2 | – | Sell |
-831
| Closed | -$32K | – | 5256 |
|
|
2015
Q1 | $32K | Buy |
+831
| New | +$33K | ﹤0.01% | 1862 |
|
|
2014
Q4 | – | Sell |
-2
| Closed | – | – | 4938 |
|
|
2014
Q3 | $0 | Sell |
2
-2,622
| -100% | -$73.9K | ﹤0.01% | 5053 |
|
|
2014
Q2 | $89K | Buy |
2,624
+890
| +51% | +$29.8K | 0.01% | 965 |
|
|
2014
Q1 | $60K | Buy |
1,734
+334
| +24% | +$15.1K | 0.01% | 968 |
|
|
2013
Q4 | $55K | Buy |
+1,400
| New | +$33.8K | 0.01% | 1303 |
|
Tower Research Capital (TRC)'s XLRN Position: Q4 2021 in Review
Tower Research Capital (TRC) sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,433 shares — an estimated $247K sold.
Tower Research Capital (TRC) first reported a position in XLRN in Q4 2013 and held it in 23 quarters. The position peaked at $1.41M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Tower Research Capital (TRC) reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,433 Acceleron Pharma shares in Q4 2021, an estimated $247K.
- Tower Research Capital (TRC) first reported a position in Acceleron Pharma in Q4 2013 and held it in 23 quarters.
- Tower Research Capital (TRC)'s Acceleron Pharma position peaked at $1.41M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2021, filed 14 Feb 2022.